MARKET

ZSAN

ZSAN

Zosano Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8021
+0.0060
+0.75%
After Hours: 0.8000 -0.0021 -0.26% 19:16 07/23 EDT
OPEN
0.8000
PREV CLOSE
0.7961
HIGH
0.8101
LOW
0.7949
VOLUME
871.02K
TURNOVER
--
52 WEEK HIGH
3.060
52 WEEK LOW
0.3275
MARKET CAP
85.61M
P/E (TTM)
-1.9445
1D
5D
1M
3M
1Y
5Y
7 Most Promising Penny Stocks to Achieve Your Multibagger Dreams
Investor Place · 2d ago
Zosano Pharma Posts Trial Titled 'Crossover Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers' To ClinicalTrials.Gov
https://clinicaltrials.gov/ct2/show/NCT04969497
Benzinga · 4d ago
BRIEF-Zosano Pharma Receives Patent For Method Of Use Of M207 For Acute Treatment Of Migraine
reuters.com · 4d ago
Zosano Pharma granted patent related to migraine treatment M207
Zosano Pharma (ZSAN) announced that it has been granted an additional patent covering method of use of M207 for the acute treatment of migraine.The patent covers methods for the release
Seekingalpha · 4d ago
Zosano Pharma Announces Issuance Of U.S. Patent For Method Of Rapidly Achieving Therapeutic Levels With M207 For The Acute Treatment Of Migraine
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No.
Benzinga · 4d ago
Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No. 11,058,630 titled Method of Rapidly Achie...
GlobeNewswire · 4d ago
15 Best Penny Stocks to Buy Now
In this article, we discuss the 15 best penny stocks to buy now. If you want to skip our detailed analysis of these companies, go directly to the 5 Best Penny Stocks to Buy Now. Many novice investors are bullish on penny stocks with growth potential for ca...
Insider Monkey · 07/14 13:11
BRIEF-Zosano Pharma Corp Files For Mixed Shelf Of Upto $150 Mln
reuters.com · 07/02 22:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZSAN. Analyze the recent business situations of Zosano Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZSAN stock price target is 2.167 with a high estimate of 2.500 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 11.64M
% Owned: 10.90%
Shares Outstanding: 106.73M
TypeInstitutionsShares
Increased
10
1.97M
New
10
455.58K
Decreased
8
741.17K
Sold Out
6
1.51M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Chief Executive Officer/Director
Steven Lo
Chief Financial Officer
Christine Matthews
Senior Vice President
Dushyant Pathak
Vice President
Eric Scharin
Other
Thorsten von Stein
Director
Linda Grais
Director
Joseph Hagan
Director
Kathy McGee
Independent Director
Steven Elms
Independent Director
Kenneth Greathouse
Independent Director
Kleanthis Xanthopoulos
No Data
About ZSAN
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its Adhesive Dermally-Applied Microarray (ADAM) technology. ADAM is an intracutaneous delivery system designed to offer drug absorption into the bloodstream. ADAM consists of an array of drug-coated titanium microneedles mounted on an adhesive backing that is pressed on to the skin using a reusable handheld applicator. The Company’s Qtrypta (M207) is a formulation of zolmitriptan delivered utilizing its ADAM technology. Qtrypta (M207) is being investigated as a treatment to provide relief of migraine symptoms in the migraine cycle. The Company has developed its transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.

Webull offers kinds of Zosano Pharma Corp stock information, including NASDAQ:ZSAN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZSAN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZSAN stock methods without spending real money on the virtual paper trading platform.